# Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

> **NCT01930006** · PHASE1 · COMPLETED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 14 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** MGCD265

## Key facts

- **NCT ID:** NCT01930006
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01930006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01930006, "Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01930006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*